Private Company Watch: Neuron23, Neurogene and Locanabio each raised $100m or more, highlighting increased investor interest in novel approaches to neurological diseases. Also, CRO dMed raised $100m and MinervaX brought in $57m for its vaccine to protect newborns. 

Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing. 

Senior executives are to depart Gilead Sciences, Bristol-Myers Squibb and Amgen, while C-suite and board hires have been reported at Sirnaomics, Pandion, Purdue Pharma, Cardurion and OncoSec.

Bioverativ revealed its first transaction since spinning out from Biogen with the acquisition of True North for $400m plus up to $425m in milestone payments. The deal gives Bioverativ a clinical asset, helping to fill the gap between preclinical programs and commercial products in its R&D pipeline.